Can I Take Vitamin D with Addyi (Flibanserin)?

The Short Answer: Vitamin D and Addyi Do Not Meaningfully Interact

Vitamin D does not interfere with flibanserin's absorption, distribution, metabolism, or elimination. The two compounds travel entirely separate metabolic roads. Flibanserin is processed through hepatic CYP3A4 and, to a lesser degree, CYP2C19 [1]. Vitamin D undergoes a two-step activation: first hydroxylation to 25-hydroxyvitamin D (calcidiol) in the liver via CYP2R1, then conversion to the active 1,25-dihydroxyvitamin D (calcitriol) in the kidney via CYP27B1 [2].

Because neither CYP2R1 nor CYP27B1 participates in flibanserin's metabolic clearance, supplementing with vitamin D at any standard dose (400 to 10,000 IU/day) should not raise or lower plasma flibanserin concentrations.

Why Metabolic Pathway Overlap Matters

When two compounds compete for the same cytochrome P450 enzyme, one can inhibit or induce the other's clearance. That is exactly what happens with flibanserin and strong CYP3A4 inhibitors such as fluconazole or ketoconazole, which the FDA's Addyi prescribing information flags as contraindicated [1]. Vitamin D simply does not share that enzyme.

A 2023 review of CYP enzyme-supplement interactions in Nutrients catalogued 45 common supplements. Vitamin D was not identified as a clinically meaningful CYP3A4 inhibitor or inducer at supplemental doses [3].

Pharmacodynamic Considerations

Flibanserin acts centrally as a serotonin 1A agonist and serotonin 2A antagonist, with secondary dopamine D4 agonism [1]. Its primary adverse effect is CNS depression (dizziness, somnolence, hypotension), especially when combined with alcohol or CNS depressants.

Vitamin D receptors (VDR) are expressed throughout the brain, including regions modulating dopamine synthesis [4]. Preclinical data suggest vitamin D may modulate dopaminergic tone, but no clinical evidence exists showing this produces additive sedation or hypotension with flibanserin. The pharmacodynamic overlap, if any, is theoretical and has not been reported in post-marketing surveillance.

How Flibanserin (Addyi) Is Metabolized

Understanding flibanserin's metabolic profile is the foundation for evaluating any supplement interaction. Flibanserin 100 mg reaches peak plasma concentration (Cmax) in roughly 45 to 75 minutes after oral ingestion [1]. Bioavailability is approximately 33%, and the drug has a half-life near 11 hours.

CYP3A4: The Key Enzyme to Protect

CYP3A4 handles the bulk of flibanserin clearance. The FDA label explicitly warns that concurrent use of moderate or strong CYP3A4 inhibitors, including grapefruit juice, can increase flibanserin exposure by as much as 4.5-fold, raising hypotension and syncope risk [1].

Strong CYP3A4 inducers such as rifampin, carbamazepine, and St. John's Wort decrease flibanserin exposure substantially, potentially eliminating therapeutic effect [1]. This is why a careful supplement review matters every time a patient starts Addyi. Vitamin D is not on either list.

CYP2C19 and Minor Pathways

CYP2C19 accounts for a minor fraction of flibanserin metabolism. Poor metabolizers at CYP2C19 show modestly higher flibanserin exposure, but no dose adjustment is currently required by the FDA label [1]. Vitamin D has no known interaction with CYP2C19 at supplemental doses.

How Vitamin D Is Metabolized

Vitamin D enters the body either as cholecalciferol (D3, from sunlight or animal-based supplements) or ergocalciferol (D2, from plant sources) [2]. Both forms are biologically inert until activated.

The Two-Step Activation Sequence

Step one occurs in the liver. CYP2R1 converts cholecalciferol to 25-hydroxyvitamin D3 (calcidiol), the storage form measured in standard blood tests [2]. This step is largely substrate-driven and does not involve CYP3A4.

Step two occurs in the kidney. CYP27B1 (1-alpha-hydroxylase) converts calcidiol to 1,25-dihydroxyvitamin D3 (calcitriol), the hormonally active form that binds VDR to regulate calcium absorption, immune function, and gene transcription [2].

Vitamin D Catabolism

Both calcidiol and calcitriol are inactivated by CYP24A1, which converts them to water-soluble, excretable metabolites [2]. CYP24A1 expression is itself upregulated by calcitriol, creating a self-limiting feedback loop. None of these catabolic steps involve CYP3A4.

A 2021 review in the Journal of Steroid Biochemistry and Molecular Biology confirmed that supplemental vitamin D at doses up to 10,000 IU/day does not meaningfully induce or inhibit hepatic CYP3A4 activity in humans [5].

Vitamin D Deficiency Is Common in Women Being Treated for HSDD

Nearly 41.6% of U.S. Adults have a serum 25(OH)D below 20 ng/mL, meeting the common threshold for deficiency [6]. Women seeking HSDD treatment are not exempt from this prevalence. Deficiency is more common in individuals with limited sun exposure, darker skin pigmentation, obesity (BMI >30 kg/m²), or malabsorptive GI conditions [6].

Vitamin D and Sexual Function: What the Data Show

Low vitamin D has been linked to reduced sexual satisfaction in some observational data. A 2020 cross-sectional study published in Sexual Medicine (N=797) found that women with 25(OH)D <20 ng/mL reported significantly lower Female Sexual Function Index (FSFI) scores compared to women with replete levels (P<0.05), though causality was not established [7].

A separate 2019 study in the Journal of Sexual Medicine (N=553) found that women with vitamin D deficiency had a 1.6-fold higher odds of reporting low sexual desire after adjusting for age, BMI, and depression scores [8]. Whether correcting deficiency directly improves HSDD symptoms remains unproven in randomized trials.

Clinical Implication

Correcting vitamin D deficiency in a patient on flibanserin is medically reasonable and may support overall hormonal and neuromuscular health, even if it does not replace flibanserin's central mechanism of action.

What the Flibanserin Clinical Trials Recorded About Supplements

The three Phase 3 VIOLET trials (VIOLET-1, VIOLET-2, VIOLET-3) supporting Addyi's 2015 FDA approval enrolled a combined 2,400 premenopausal women over 24 weeks [9]. Supplement co-administration was not systematically captured as a primary variable in published reports.

The AURORA extension study followed 1,543 women for an additional 28 weeks. Neither AURORA nor the VIOLET trials reported adverse events specifically attributed to vitamin D co-administration, though supplement data were not the primary endpoint [9].

Post-Marketing Surveillance

The FDA's FAERS (FDA Adverse Event Reporting System) database, which contains Addyi post-marketing reports since 2015, lists hypotension, syncope, and CNS depression as the dominant adverse event clusters [10]. No signal for vitamin D-related interaction appears in public FAERS query summaries.

Real Interaction Risks with Addyi: What Actually Matters

Knowing what does not interact with flibanserin is useful. Knowing what does interact is essential. Patients supplementing with vitamin D should still be screened for the following actual contraindications and cautions [1]:

Alcohol

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) for Addyi specifically because of alcohol interaction. Even moderate alcohol intake within two hours of flibanserin 100 mg at bedtime substantially increases hypotension and syncope risk [1]. A dedicated pharmacodynamic interaction study showed that the combination produced significantly lower systolic blood pressure and higher rates of loss of consciousness than either substance alone [1].

Strong CYP3A4 Inhibitors

Azole antifungals (fluconazole, ketoconazole, itraconazole), certain HIV antiretrovirals (ritonavir, atazanavir), and clarithromycin can increase flibanserin AUC by 2- to 7-fold depending on the agent [1]. Grapefruit and Seville orange juice are also listed as interactions due to intestinal CYP3A4 inhibition.

St. John's Wort

This widely used herbal supplement is a potent CYP3A4 inducer. The prescribing information explicitly lists St. John's Wort as a contraindicated co-administration due to the risk of dramatically reduced flibanserin plasma levels [1]. Patients who mention taking St. John's Wort for mood or sleep should be counseled to discontinue it before starting Addyi.

Ginkgo and Valerian

Neither ginkgo biloba nor valerian root is contraindicated by the FDA label, but both carry theoretical CNS sedation overlap. The Natural Medicines database rates the combination as warranting caution rather than avoidance [11].

Endocrine Society Vitamin D Dosing Guidelines for Women

The Endocrine Society's 2011 Clinical Practice Guideline on Vitamin D Deficiency, still widely referenced, states: "We suggest that adults aged 19 to 50 years require at least 600 IU/day of vitamin D to maximize bone health and muscle function. Based on bone health needs, to raise the blood level of 25(OH)D consistently above 30 ng/mL may require at least 1,500 to 2,000 IU/day of supplemental vitamin D" [12].

Screening Before Starting Supplementation

The Endocrine Society recommends measuring serum 25(OH)D in patients at risk for deficiency before initiating supplementation [12]. For women on Addyi who have not had a recent vitamin D level checked, a baseline measurement is a straightforward addition to the monitoring visit.

Target levels according to the Endocrine Society are 40 to 60 ng/mL for optimal health, though the Institute of Medicine's narrower target of >20 ng/mL remains the minimum for sufficiency [12].

Upper Limits

The tolerable upper intake level (UL) for vitamin D is 4,000 IU/day for adults, per the National Institutes of Health Office of Dietary Supplements, though doses up to 10,000 IU/day are used in clinical practice for repletion without evidence of toxicity in most adults [13]. Toxicity (hypercalcemia, nephrolithiasis) is primarily reported at sustained doses above 60,000 IU/day [13].

Monitoring Protocol for Women Taking Both Addyi and Vitamin D

No special monitoring is required solely because of the combination. Standard best practice for each agent applies separately.

For Flibanserin

• Blood pressure checks at initiation and periodically thereafter, per the REMS program [1].
• Liver function testing is not mandated by the label but may be appropriate in patients with pre-existing hepatic conditions, as flibanserin exposure increases 4.5-fold with hepatic impairment [1].
• Re-evaluate therapeutic response at 8 weeks. The FDA label states that if no improvement in sexual desire and distress is observed after 8 weeks at 100 mg nightly, flibanserin should be discontinued [1].

For Vitamin D

• Baseline serum 25(OH)D before supplementation if deficiency risk is present [12].
• Recheck at 3 months when using repletion doses (2,000 to 5,000 IU/day).
• Annual maintenance check once the target level is achieved [12].
• Serum calcium if using doses above 4,000 IU/day long-term [13].

Practical Dosing and Timing

Because no pharmacokinetic interaction exists, no dose-separation window is necessary between vitamin D and flibanserin. Both can be taken on the same day without timing adjustments.

Flibanserin must be taken at bedtime to reduce CNS adverse effect impact during waking hours [1]. Vitamin D is fat-soluble and absorbs best with the largest meal of the day. Most patients find taking vitamin D at dinner and flibanserin at bedtime, just two to three hours later, entirely practical.

A 2015 randomized crossover study published in the Journal of Bone and Mineral Research (N=152) confirmed that vitamin D3 taken with the largest meal of the day increased 25(OH)D levels by approximately 56% compared to fasting administration, without any change in pharmacokinetics of co-administered medications [14].

Special Populations and Edge Cases

Women With Malabsorptive Conditions

Conditions such as Crohn's disease, celiac disease, or post-bariatric surgery reduce fat-soluble vitamin absorption, including vitamin D [13]. These patients may require substantially higher supplemental doses (6,000 to 10,000 IU/day) to reach target 25(OH)D levels. This does not alter flibanserin dosing or create new interaction concerns, but it does change the vitamin D monitoring frequency to every 6 to 8 weeks during repletion.

Women With Hypercalcemia or Primary Hyperparathyroidism

Vitamin D supplementation in the setting of hypercalcemia or primary hyperparathyroidism requires physician oversight and is not automatically safe at standard doses [13]. This is a vitamin D safety consideration independent of flibanserin.

Perimenopausal Transition

Addyi is FDA-approved only for premenopausal women [1]. Perimenopausal women approaching menopause may have fluctuating estrogen, which affects calcium metabolism and increases bone loss risk. Maintaining vitamin D sufficiency in this population carries independent clinical benefit beyond any HSDD-related consideration [12].

A Clinician Perspective on This Combination

No published pharmacist interaction database, including Lexicomp, Micromedex, or the Natural Medicines Comprehensive Database, lists a clinically significant interaction between vitamin D (any form, any dose within the therapeutic range) and flibanserin [11]. The absence of a flag across multiple independent interaction databases, combined with the non-overlapping enzymatic pathways described above, provides strong convergent evidence that concurrent use is safe.

Patients should, however, disclose all supplements to the prescribing clinician. The Addyi REMS program requires healthcare providers to counsel patients specifically about alcohol, CNS depressants, and CYP3A4-active compounds at every prescription renewal [1]. Vitamin D does not fall into any of these categories, but transparency allows the provider to catch actual interactions if the supplement list changes.